AI helps Stanford scientists discover “natural Ozempic” without the usual side effects
Saturday, July 25 – Stanford Medicine researchers have discovered a naturally occurring molecule that may suppress appetite and reduce body weight much like Ozempic, but without several of its common side effects. The molecule, called BRP, acts on a more targeted region of the brain involved in hunger and metabolism rather than affecting tissues throughout the body.
The billion-dollar problem keeping Ozempic, Wegovy, and Zepbound from patients
Saturday, July 25 – Ozempic, Wegovy, and similar drugs may deliver excellent health value, but covering them for millions of eligible patients could overwhelm insurance budgets. Researchers say better long-term support is needed and warn that low-cost compounded versions may carry serious safety risks.
Ozempic and Mounjaro linked to a surprising hair loss risk
Saturday, July 25 – A large study suggests that GLP-1 drugs including Ozempic and Mounjaro may slightly increase the risk of hair loss in people with type 2 diabetes. Compared with two other common classes of diabetes medications, GLP-1 users had a significantly higher rate of alopecia, though the absolute risk was still low. The hair loss was mainly non-scarring, which means it may be reversible.
Lilly’s triple-G retatrutide ‘best-in-class’ as BLA filing nears
Friday, July 24 – Scoring high marks on two more phase III obesity trials, this time involving serious type 2 diabetes and cardiovascular complications, Eli Lilly and Co. has cleared the path for a BLA filing for its triple-G candidate retatrutide, which many expect will eventually surpass the top two marketed drugs in the space.
A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing
Friday, July 24 – Has a wanted fugitive been posing as a biotech executive? And what does it take to develop a therapy for an ultra-rare disease? Find out on this week’s episode of…
GLP-1 diabetes drugs linked to up to 68% higher hair loss risk
Thursday, July 23 – July The use of glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes and obesity is associated with an increased risk of hair loss (alopecia) in adults with type 2 diabetes, a study published by The BMJ finds. Although the absolute risk is low, awareness of this potential effect may help inform shared treatment decisions, the researchers say.
New Study Links GLP-1s to Hair Loss
Thursday, July 23 – (MedPage Today) — Adults with type 2 diabetes who used a GLP-1 receptor agonist had an increased risk of clinically recorded hair loss, data from a target trial emulation suggested.
Compared with other antidiabetic medications, GLP-1 drug use…
GLP-1s for Addiction; DEA’s Ketamine Crackdown; ADHD and Social Media
Thursday, July 23 – (MedPage Today) — The use of GLP-1 receptor agonists was associated with a lower risk of alcohol-related hospitalization in adults with alcohol addiction, a retrospective study found. (BMJ Open)
GLP-1 drugs for obesity were linked with reduced…
Semaglutide sustains lower calorie intake for more than a year, study shows
Wednesday, July 22 – People taking semaglutide for weight loss continued to consume significantly fewer calories after 60 weeks on the medication, helping explain how the medication supports both initial weight loss and long-term weight maintenance. The study, published in the American Journal of Clinical Nutrition and led by investigators from Penn’s Center for Weight and Eating Disorders and Penn Metabolic Medicine, is among the first to examine the long-term effects of semaglutide on eating behavior beyond the initial months of treatment.
Examining the consequences of discontinuing GLP-1 medications on addiction-related hospitalizations
Wednesday, July 22 – GLP-1 receptor agonists are among the active ingredients in so-called weight-loss injections. Originally developed to treat type 2 diabetes, they are now also used to treat severe obesity. In recent years, studies have provided evidence that they may also reduce the consumption of alcohol and other substances. However, it has not been clear whether these potential effects persist after the medication is discontinued.